Cytokinetics adds pharma veteran Landry to board ahead of drug launch
SOUTH SAN FRANCISCO - Cytokinetics , Incorporated (NASDAQ:CYTK), currently valued at approximately $5 billion in market capitalization, has announced the appointment of Robert E. Landry to its Board ...
Cytokinetics Names Robert E. Landry to Board of Directors
Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential CommercializationSOUTH SAN FRANCISCO, Calif., ...
Why Cytokinetics, Incorporated (CYTK) Is Among the Best Healthcare Stocks To Buy According to Analysts
We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...
Cytokinetics draws new Buy from Citi on aficamten potential
Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset aficamten. Read more here.
Citi sets $86 price target on Cytokinetics stock with buy rating
Citi initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and an $86.00 price target, representing significant upside from the current price of $46.17. The firm's analysts highlighted ...
Cytokinetics initiated with a Buy at Citi
Citi initiated coverage of Cytokinetics (CYTK) with a Buy rating and $86 price target. The shares seem attractive at current levels, given the ...